Pre-CTA Report · for pharma service providers

The biotechs preparing their first CTA right now. Before your competitors call.

Between preclinical work and the first study in humans, a biotech awards almost everything for the first time: dossier, manufacturing, release, the trial. Whoever calls in these months becomes the partner for years. Kodo shows you which companies are there now, and where it says so.

For regulatory consultancies, CROs, CDMOs, labs and QP providers in Europe

Request the report

Price on request, with a sample page from your therapeutic area.

What we mean by “pre-CTA”.

Pre-CTA is our name, not an industry term. In the US the same period is called IND-enabling, after the application to the FDA. Others speak of preparing for first-in-human, or the company announces that it is becoming a “clinical-stage company”. It always means the same step: a compound leaves the lab and goes into the first study in humans.

In Europe this step ends with the CTA, the application to authorise the clinical trial. By then the biotech needs a regulatory partner, a lab for analytics, a manufacturer for the investigational product, a QP for release and a CRO for the trial. Almost all of it is awarded for the first time.

That is why timing matters. A year too early, there is nothing to award. A year too late, the trial is recruiting and you are negotiating against a provider who is already there.

Four stages to the first patient.

The contracts are awarded in the first two. By the third, it is usually decided who is in.

  1. Lab work donePreclinical work is complete. Needed: analytics and stability.
  2. Preparing the filingAdvice from the regulator, dossier, first GMP batch. Needed: regulatory, manufacturer and QP.
  3. Filing under reviewSubmission via CTIS, about two months of assessment.
  4. First patientThe trial starts. Needed: CRO and sites.
About two months: ten days validation, 45 days assessment, five days decision, without questions from the authorities (Regulation (EU) No 536/2014, Articles 5 to 8).

How we spot it.

Most companies say it themselves. The pipeline page names the planned trial start, the funding announcement says “to advance into first-in-human”, the careers page shows the first regulatory affairs position. On top come the trial registries, EMA decisions and the attendee lists of partnering conferences. A single hint is not enough for us, and every company is listed with the source that puts it in the window.

Kodo Pre-CTA Report New in the window this week
  1. AcuteBiotech, Munich: phase 1 start of its first programme announced for Q2.

    Company pipeline page

  2. NewBiotech, Vienna: series A “to advance into first-in-human trials”.

    Company press release

  3. SoonBiotech, Basel: first “Head of Regulatory Affairs” position posted.

    Company careers page

Sample rows, company names removed. Acute means: filing within six months is documented.

Request the report. With a sample page.

Tell us which services you offer and for which indications. You get a sample page from your area and a quote. Rather talk right away? Book a call with Joshua.

We only use your details for this request and any follow-up question about it. Privacy

Frequently asked questions

Is “pre-CTA” an official term?

No. It is our name for the phase before the first clinical trial application. In the US it is called IND-enabling; people also speak of preparing for first-in-human.

What is a CTA?

The clinical trial application, the request to authorise a clinical trial. In the EU it has been filed through the CTIS portal since 2023 and assessed by the national authorities.

What is the difference between a CTA and an IND?

Both are the application for the first clinical trial. The CTA is filed in the EU through CTIS, the IND with the US FDA. Many European biotechs file both, often the CTA first.

How early before the application do you spot a company?

Usually six to 24 months before. We call a company acute when an application or trial start within the next six months is documented, for example an announced date or funding explicitly for the first study.

What about companies with a single hint?

A job ad alone is not enough for “acute”. Such companies appear under “soon”, with a note on what is missing. Nothing undocumented goes on the list.

How often is the list updated?

With a subscription, every week. New companies in the window are flagged; companies that are already recruiting or whose programme was stopped drop out.

Can I filter by indication or modality?

Yes. In the first call we clarify which indications, modalities (small molecules, antibodies, cell and gene therapy) and countries matter for your services. You only get those.

Which countries does the report cover?

Europe, with a focus on Germany, Austria and Switzerland. Biotechs from other regions are included when they plan to file in the EU.

How is this different from a biotech database?

Databases deliver funding rounds and company profiles. The report answers one question: who needs a partner for their first clinical application now, and where does it say so?

What does the report cost?

The price depends on countries and services. You get a quote before you sign.

More on the application itself: What is a CTA?. Otherwise Kodo finds target customers among industrial SMEs, and for companies going abroad there is the market entry report.